Kyntra Bio stock gains 16.83 percent to EUR 4.72 at Lang & Schwarz

Published on 10/20/2026 at 22:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Nasdaq review may last 180 days. Kyntra Bio stock costs EUR 4.72 on October 20, 2026, up 16.83 percent versus the Frankfurt close.

Delisting review and quarterly figures

Kyntra Bio requested a Nasdaq hearing on October 6, 2026, with a possible extension of up to 180 days.
Second-quarter 2026 revenue was negative USD 1.47 million versus USD 1.30 million a year earlier.
Kyntra Bio stock costs EUR 4.72 at Lang & Schwarz on October 20, 2026 at 10:00 p.m. CEST, 16.83 percent above the Frankfurt close of October 19, 2026.

KYNB, US31572Q8814, Illustration mit AI erstellt.

Kyntra Bio (ISIN US31572Q8814) was trading 16.83 percent above the Frankfurt close on October 20, 2026, as the company continued to address a Nasdaq listing challenge. In a Form 8-K filed on October 6, 2026, the SEC recorded that Kyntra Bio had requested a hearing after Nasdaq staff determined that the company had not demonstrated compliance with Listing Rule 5450(b). Kyntra Bio stock was trading at EUR 4.72 at Lang & Schwarz on October 20, 2026 at 10:00 p.m. CEST, up 16.83 percent versus the Frankfurt close of EUR 4.04 on October 19, 2026.

Nasdaq review sets a 180-day window

The hearing request keeps the common stock listed and trading while the Nasdaq Hearings Panel reviews the staff determination. The filing states that an extension could last up to 180 days, while Kyntra Bio prepares a compliance plan. The company had received the determination after failing to demonstrate compliance with a standard requiring at least USD 50.00 million in total assets and USD 50.00 million in total revenue for the relevant fiscal-year test.

Second-quarter revenue turned negative

Kyntra Bio reported negative USD 1.47 million of revenue for the second quarter of 2026, compared with USD 1.30 million in the second quarter of 2025, according to the Yahoo Finance earnings-call transcript. Net income from continuing operations was USD 12.00 million, compared with a USD 13.70 million loss in the year-earlier quarter. Operating costs and expenses increased to USD 16.10 million from USD 13.40 million.

Clinical milestones remain dated for 2026

The same August 13, 2026 earnings call said Kyntra Bio expected an interim analysis of 36 patients in its phase-two FG-3246 trial during the fourth quarter of 2026. Management also described the company as targeting the start of a phase-three roxadustat trial in the fourth quarter of 2026. These milestones are operating dates rather than completed results, so the listing review and the cash profile remain important parts of the stock discussion.

Market value and trading frame

Kyntra Bio had a market capitalization of USD 21.3 million and a Nasdaq 52-week range of USD 4.85 to USD 11.65 as of October 20, 2026. Its USD 5.26 Nasdaq quote at 3:59 p.m. ET was separate from the euro quotation used for German investors. The company profile identifies Kyntra Bio as a healthcare biotechnology business with 34 full-time employees.

Trading stays tied to the listing decision

The October 6 filing says the hearing request stays suspension proceedings while the panel considers the case. For shareholders, the key numerical contrast is between the USD 50.00 million Nasdaq asset and revenue thresholds and the USD 21.3 million equity market value shown for Kyntra Bio, although those measures are not identical tests.

Kyntra Bio stock was trading at EUR 4.72 at Lang & Schwarz on October 20, 2026 at 10:00 p.m. CEST, 16.83 percent above the Frankfurt close of EUR 4.04 on October 19, 2026. The price move places the current euro quotation below the Nasdaq 52-week low after currency differences are considered, so the two venue ranges should not be compared directly. The further course of trading is shown by the continuously updated real-time quote of Kyntra Bio stock.